Predicting treatment outcomes for men with advanced prostate cancer using genetic information
Official title: Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC
Funded at Duke University · NIH-11009561 · Data updated 2026-11-12
This study is looking to help men with advanced prostate cancer figure out if they will benefit from certain hormone therapies, so they can get the right treatment and avoid side effects from medications that might not work for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | September 16, 2020 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $647,291 |
| NIH project number | 5R01CA256157-05 |
| Project ID | NIH-11009561 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who are considering first-line androgen receptor inhibitor therapies.
✕Less likely to help
Patients who do not have metastatic castration-resistant prostate cancer or those who are not candidates for androgen receptor inhibitor therapies may not benefit from this research.
What this research studies
This research aims to develop a clinical genomic predictive model to help determine which men with metastatic castration-resistant prostate cancer (mCRPC) will benefit from first-line androgen receptor inhibitor therapies like enzalutamide or abiraterone acetate. By analyzing genetic biomarkers, the study seeks to identify patients who are likely to experience durable benefits from these treatments, thereby optimizing therapy and minimizing unnecessary side effects for those unlikely to respond. The approach involves collecting and analyzing patient data to create a model that can guide treatment decisions. This could lead to more personalized and effective care for men facing this challenging condition.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for men with advanced prostate cancer by ensuring they receive the most effective therapies based on their genetic profiles.
How similar studies have gone: Previous research has shown promise in using genomic biomarkers to predict treatment responses in various cancers, suggesting that this approach could be effective in prostate cancer as well.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Halabi, Susan — Duke University
- Study coordinator: Halabi, Susan
Related research
Other NIH-funded projects on the same topics.
-
Dual Targeting of B7-H3 in metastatic prostate cancer
A Johns Hopkins team is testing two targeted therapies against B7-H3 to help people with metastatic castration-resistant prostate cancer feel better and show tumor responses.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Extending Benefit by Targeting Resistant Lesions in mCRPC
A cancer center plans to identify on-treatment resistant spots in men with metastatic castration-resistant prostate cancer and then use targeted local therapy to those spots while systemic treatment continues.
-
CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer
A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.
-
Multidimensional approach to boost PSMA-RPT success in advanced prostate cancer
A cancer research grant aims to better understand why PSMA-targeted radiopharmaceutical therapy works sometimes but not always for advanced prostate cancer, with the goal of making treatments more effective for patients who need them.
-
Targeted radiation approach for prostate cancer without continuous castration
A study testing a targeted radiation plan for men with metastatic castration-resistant prostate cancer to improve outcomes and quality of life by avoiding continuous castration for those receiving PSMA-directed therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.